三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图表50艾玛昔替尼II/III期AS临床数据(应答率)
图表50艾玛昔替尼II/III期AS临床数据(应答率)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:423KB
图片尺寸:1149*1109
同报告图片
/
4
fCDmjIfmoIcgICAgICAgfCDlr7nnhafnu4TlupTnrZTnjocoJSkgfCDor5Xpqoznu4TlupTnrZTnjocoJSkgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18CnwgQVNBUzIwICAgICB8IDI5LjAgICAgICAgICAgICAgfCA0OC43ICAgICAgICAgICAgIHwKfCBBU0FTNDAgICAgIHwgMTguMyAgICAgICAgICAgICB8IDMyLjEgICAgICAgICAgICAgfAp8IEFTQVM1LzYgICAgfCAxNS42ICAgICAgICAgICAgIHwgNDIuOCAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpaLkxpIGV0IGFsLiBBIG11bHRpY2VudGVyLCByYW5kb21pemVkLCBkb3VibGUgLSBibGluZCw=
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
所属报告:
恒瑞医药(600276)-A股公司深度研究报告系列一:创新与国际化赋能国产创新龙头渐入佳境-250926(41页).pdf
打包全文图表
相关数据
图表51艾玛昔替尼II/III期AS数据(较基线变化)
fCDmjIfmoIcgICAgICAgICAgfCBQbGFjZWJvIHwgU0hSMDMwMiA0IG1nIHwKfC0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgQkFTREFJICAgICAgICB8IC0xLjQzICAgfCAtMi4yMSAgICAgICAgfAp8IEJBU0ZJICAgICAgICAgfCAtMC43OSAgIHwgLTEuMzMgICAgICAgIHwKfCBCQVNNSSAobGluZWFyKXwgLTAuMjkgICB8IC0wLjQwICAgICAgICB8CnwgQVNRb0wgICAgICAgICB8IC0yLjE4ICAgfCAtMy4xMyAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaWi5MaSBldCBhbC4gQSBtdWx0aWNlbnRlciwgcmFuZG9taXplZCwgZG91YmxlLWJsaW5kLA==
收藏
行业数据
2025-09-28
原图定位
查看详情
图34、罗昔替尼各适症国内与美国发进
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
收藏
行业数据
2025-08-19
原图定位
查看详情
吉卡昔替尼乳膏临床试验情况(截至2025.05.29)
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
收藏
行业数据
2025-08-01
原图定位
查看详情
戈利昔替尼与西达本胺的PFS曲线对比
5Lul5LiL5piv5o+Q5Y+W55qE5pWw5o2u5bm255Sf5oiQ55qE6KGo5qC877yaCgp8IOaXtumXtO+8iOaciO+8iSB8IOaIiOWIqeaYlOabv+WwvOeUn+WtmOamgueOhyB8IOilv+i+vuacrOiDuueUn+WtmOamgueOhyB8CnwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLXwKfCAwICAgICAgICAgIHwgMTAwJSAgICAgICAgICAgICAgfCAxMDAlICAgICAgICAgICAgfAp8IDUgICAgICAgICAgfCA3NSUgICAgICAgICAgICAgICB8IDc1JSAgICAgICAgICAgICB8CnwgMTAgICAgICAgICB8IDUwJSAgICAgICAgICAgICAgIHwgNTAlICAgICAgICAgICAgIHwKfCAxNSAgICAgICAgIHwgMjUlICAgICAgICAgICAgICAgfCAyNSUgICAgICAgICAgICAgfAp8IDIwICAgICAgICAgfCAyNSUgICAgICAgICAgICAgICB8IDAlICAgICAgICAgICAgICB8CnwgMjUgICAgICAgICB8IDI1JSAgICAgICAgICAgICAgIHwgMCUgICAgICAgICAgICAgIHwKfCAzMCAgICAgICAgIHwgMjUlICAgICAgICAgICAgICAgfCAwJSAgICAgICAgICAgICAgfAp8IDM1ICAgICAgICAgfCAyNSUgICAgICAgICAgICAgICB8IDAlICAgICAgICAgICAgICB8CnwgNDAgICAgICAgICB8IDI1JSAgICAgICAgICAgICAgIHwgMCUgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWbveWutuWMu+eWl+S/nemanOWxgO+8jOiCsuWFtOivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与西达本胺不同亚型PTCL的ORR
fCDliIbnsbsgfCDmiIjliKnmmJTmm7/lsLwgWzFdIHwg6KW/6L6+5pys6IO6IFsyXSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwKfCDooYDnrqHlhY3nlqvmr43nu4bog55U57uG6IOe5reL5be055ikIChBSVRMKSB8IDU2JSB8IDUwJSB8Cnwg6Z2e54m55oyH5Z6L5aSW5ZGoVOe7huiDnua3i+W3tOeYpCAoUFRDTC1OT1MpIHwgNDYlIHwgMjIlIHwKfCDoh6rnhLbmnYDkvKQvVOe7huiDnua3i+W3tOeYpCAoTksvVENMKSB8IDY3JSB8IDE5JSB8Cnwg5YW25LuW5Lqa5Z6LIHwgNDQlIHwgMTElIHw=
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与已获批竞品疗效对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与其它JAK抑制剂的选择性比较
5aW955qE77yM5Lul5LiL5piv5oKo5Zu+54mH5Lit55qE5pWw5o2u55Sf5oiQ55qE6KGo5qC877yM5bm25Zyo6KGo5qC85LiL5pa55bGV56S65LqG6LWE5paZ5p2l5rqQ77yaCgp8IEpBSzHpnbbngrnnmoTpgInmi6nmgKflgI3mlbAgfCDmiIjliKnmmJTmm7/lsLwgfCDoiqblj6/mm7/lsLzvvIhSdXhvbGl0aW5pYu+8iSB8IEZlZHJhdGluaWIgfCBJdGFjaXRpbmliIHwgTW9tZWxvdGluaWIgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS18CnwgSkFLMSAgICAgICAgICAgICAgICAgfCAxICAgICAgICAgIHwgMSAgICAgICAgICAgICAgICAgICAgICAgfCAxICAgICAgICAgIHwgMSAgICAgICAgICB8IDEgICAgICAgICAgIHwKfCBKQUsyICAgICAgICAgICAgICAgICB8ID4yMDAgICAgICAgfCAwLjggICAgICAgICAgICAgICAgICAgICB8IDAuMDMgICAgICAgfCAyMiAgICAgICAgIHwgMS42ICAgICAgICAgfAp8IEpBSzMgICAgICAgICAgICAgICAgIHwgPjQwMCAgICAgICB8IDEzICAgICAgICAgICAgICAgICAgICAgIHwgOS41ICAgICAgICB8ID42MDAgICAgICAgfCAxNCAgICAgICAgICB8CnwgVFlLMiAgICAgICAgICAgICAgICAgfCA+NDAwICAgICAgIHwgNiAgICAgICAgICAgICAgICAgICAgICAgfCAzLjkgICAgICAgIHwgMjU2ICAgICAgICB8IDEuNSAgICAgICAgIHwKCui1hOaWmeadpea6kO+8mui/quWTsuWMu+iNrzIwMjXlubQz5pyI5YWs5ZGK77yM55Ss5YW06K+B5Yi456CU56m25omA
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与西达本胺临床疗效对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与西达本胺停药率对比
5qC55o2u5oKo5o+Q5L6b55qE5L+h5oGv77yM5Lul5LiL5piv6KGo5qC85ZKM6LWE5paZ5p2l5rqQ77yaCgp8IOiNr+eJqSAgICAgICB8IOWBnOiNr+eOhyAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tfAp8IOaIiOWIqeaYlOabv+WwvCB8IDcuMyUgICB8Cnwg6KW/6L6+5pys6IO6ICAgfCAxNi45JSAgfAoK6LWE5paZ5p2l5rqQ77ya5Zu95a625Yy755aX5L+d6Zqc5bGA77yM6byO5YW06K+B5Yi456CU56m25omA
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与其它JAK抑制剂的PK比较
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
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼与已获批竞品安全性对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
戈利昔替尼临床开发历程
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
收藏
产业概述
2025-02-06
原图定位
查看详情
POETYKPSO-LTE:2年期氘可来昔替尼用药安全性结果
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM55Sf5oiQ55qE6KGo5qC85aaC5LiL77yaCgp8IOmhueebriAgICAgICAgIHwg5q+U5L6LICglKSB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tfAp8IFNBRSAgICAgICAgICB8IDkuNSAgICAgIHwKfCDlr7zoh7TlgZzoja8gQUUgIHwgNC41ICAgICAgfAp8IOatu+S6oSAgICAgICAgIHwgMC41ICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaQnIgSiBEZXJtYXRvbC4gMjAyNDsxOTAoNSk6NjY4LTY3Oe+8jOWNjuazsOeglOeptg==
收藏
行业数据
2024-12-30
原图定位
查看详情
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率
fCDoja/nianlj4rliYLph48gfCBBQ1ItMjDnvJPop6PnjocgKCUpIHwKfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCDmsKLlj6/mnaXmmJTmm7/lsLw2bWcgcWQgKE49NzApIHwgNTAgfAp8IOawouWPr+adpeaYlOabv+WwvDEybWcgcWQgKE49NjcpIHwgNjAgfAp8IOWuieaFsOWJgiAoTj02NikgfCAzMCB8CgrotYTmlpnmnaXmupDvvJpBbm4gUmhldW0gRGlzLiAyMDIyOzgxKDYpOjgxNS04MjLvvIzljY7ms7DnoJTnqbY=
收藏
行业数据
2024-12-30
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
艾玛昔替尼临床数据优异。在 2024 欧洲风湿病学大会(EULAR)汇报了艾玛昔替尼 AS和 RA 适应症的关键临床数据。其中,AS 适应症的 II/III 期研究结果显示,第 12 周SHR0302 4mg 组的 ASAS20 应答率为 48.7%,显著高于安慰剂组的 29.0%(P=0.0001);与安慰剂相比,SHR0302 4mg 组在 ASAS40(32.1% vs. 18.3%,P=0.0011)和 ASAS5/6 应答(42.8% vs. 15.6%, P<0.0001)方面也有显著改善,安全性与耐受性良好。
行业数据
原图定位
当前图表所属:
恒瑞医药(600276)-A股公司深度研究报告系列一:创新与国际化赋能国产创新龙头渐入佳境-250926(41页).pdf
表24PD-L1/TGF-β双抗作用机制
图表8恒瑞医药2018-2025H1三费率
图表7恒瑞医药收入与扣非净利润
图表63恒瑞医药可比公司估值
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》